335 related articles for article (PubMed ID: 15168086)
1. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
2. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.
Yun CO; Nolan KF; Beecham EJ; Reisfeld RA; Junghans RP
Neoplasia; 2000; 2(5):449-59. PubMed ID: 11191112
[TBL] [Abstract][Full Text] [Related]
3. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
[TBL] [Abstract][Full Text] [Related]
4. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
6. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Eshhar Z; Waks T; Gross G; Schindler DG
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):720-4. PubMed ID: 8421711
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Suzuki M; Curran KJ; Cheung NK
Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
[TBL] [Abstract][Full Text] [Related]
9. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
[TBL] [Abstract][Full Text] [Related]
10. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.
Hombach A; Pohl C; Reinhold U; Abken H
Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789
[TBL] [Abstract][Full Text] [Related]
11. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!].
Riffard C; Teillaud JL
Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800
[TBL] [Abstract][Full Text] [Related]
12. Genetic approaches for antigen-selective cell therapy.
Alvarez-Vallina L
Curr Gene Ther; 2001 Nov; 1(4):385-97. PubMed ID: 12109064
[TBL] [Abstract][Full Text] [Related]
13. Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy.
Ren-Heidenreich L; Lum LG
Curr Gene Ther; 2001 Sep; 1(3):253-5. PubMed ID: 12109140
[TBL] [Abstract][Full Text] [Related]
14. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
Zhuang X; Long EO
Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
Rossig C; Bollard CM; Nuchtern JG; Rooney CM; Brenner MK
Blood; 2002 Mar; 99(6):2009-16. PubMed ID: 11877273
[TBL] [Abstract][Full Text] [Related]
16. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
17. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
18. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
[TBL] [Abstract][Full Text] [Related]
19. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes.
Rossig C; Bollard CM; Nuchtern JG; Merchant DA; Brenner MK
Int J Cancer; 2001 Oct; 94(2):228-36. PubMed ID: 11668503
[TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance and immunity by redirected B cell-specific cytolytic T lymphocytes.
Nguyen P; Duthoit CT; Geiger TL
Gene Ther; 2007 Dec; 14(24):1739-49. PubMed ID: 17928872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
